Pipeline

Despite significant advances in endocrinology, there are still large unmet needs for effective and safe treatments. We are building, expanding and rapidly advancing a pipeline of innovative peptides and proteins.

Therapeutic peptides and proteins are particularly well suited as drugs for endocrine diseases because many hormones are peptides or proteins or proteins.

Discovery and Research Pre-clinical IND-Enabling Upcoming Milestones Commercial Rights Phase 1 Phase 2 Phase 3 Eneboparatide (AZP-3601) Hypoparathyroidism Launch Phase 3 clinical trial in H1 2023 Launch Phase 1 clinical trial in H1 2023 AZP-3813 Acromegaly AZP-40XX Drug candidate selection Primary hyperparathyroidism Humoral hypercalcemia of malignancy Exclusive option to license

Our portfolio currently includes:

  • Eneboparatide, a potential treatment for hypoparathyroidism
  • AZP-3813, a potential treatment for acromegaly
  • AZP-40XX , a potential treatment(s) for primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM)

With our team’s established expertise in therapeutic peptides and proteins, we aim to further expand and rapidly advance our pipeline of promising innovative peptides and monoclonal antibodies through global approval.

partnerships

Massachusetts General Hospital (MGH)

Peptidream Inc.

Xoma Corp.

Scroll to Top